MedTrace Logo

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

NCT03278028 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2019-04-09

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.

Conditions

  • Common Wart

Interventions

DRUG

A-101 Topical Solution

A-101 Topical Solution

DRUG

A-101 Vehicle Solution

A-101 Vehicle Solution

Sponsors & Collaborators

  • Aclaris Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Stuart D Shanler, MD · Aclaris Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-13
Primary Completion
2018-03-01
Completion
2018-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03278028 on ClinicalTrials.gov